Company Overview

Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted cancer therapies guided by functional cellular signaling biology. The company operates within the biopharmaceutical and oncology industries, with an emphasis on precision medicine approaches designed to identify and treat patients most likely to benefit from specific pathway-targeted drugs.

Celcuity’s core value proposition is built around its proprietary CELsignia® platform, a functional proteomics technology designed to measure live-cell signaling activity rather than static biomarkers. This platform is used to identify oncogenic pathway activation that may not be detectable through genomic testing alone. Founded in 2012 and headquartered in the United States, the company transitioned from platform-focused diagnostics toward drug development following the in-licensing of a late-stage oncology asset, positioning itself as a therapeutics-driven precision oncology company.

Business Operations

Celcuity’s operations center on a single reportable segment: oncology drug development, supported by its CELsignia® signaling analysis platform. The company’s primary drug candidate is gedatolisib, a dual PI3K/mTOR inhibitor originally developed by Pfizer Inc. and subsequently licensed to Celcuity. Gedatolisib is being evaluated primarily in hormone receptor–positive (HR+), HER2-negative breast cancer, including patients with resistance to standard-of-care therapies.

The company currently generates no commercial revenue and funds operations through equity financing and public market capital. Research and development activities are conducted primarily through internal teams and third-party clinical research organizations. Celcuity does not have approved products and does not operate manufacturing facilities, relying instead on external partners for drug supply and clinical execution.

Strategic Position & Investments

Strategically, Celcuity is focused on advancing gedatolisib through late-stage clinical development while differentiating its program through biologically informed patient selection. The company’s development strategy emphasizes combination regimens with established endocrine and targeted therapies to address unmet needs in breast cancer populations with pathway-driven resistance.

A defining strategic investment was the acquisition of rights to gedatolisib from Pfizer Inc., which significantly reshaped the company’s trajectory from a diagnostics-oriented platform company into a therapeutics-focused oncology developer. Celcuity continues to invest in expanding the clinical and translational applications of the CELsignia® platform, particularly in identifying PI3K/mTOR pathway activation beyond genomics, though broader pipeline diversification remains limited based on publicly available disclosures.

Geographic Footprint

Celcuity is headquartered in Minnesota, United States, and its operations are primarily U.S.-based. Clinical trials, however, involve investigational sites across North America and Europe, reflecting the global nature of oncology drug development and patient recruitment.

While the company does not maintain international commercial operations, its clinical development activities and regulatory engagement extend internationally through trial sites and regulatory jurisdictions. Celcuity’s geographic footprint remains relatively concentrated compared to larger biopharmaceutical peers, consistent with its clinical-stage profile.

Leadership & Governance

Celcuity is led by an executive team with experience in oncology drug development, clinical research, and life sciences finance. The leadership emphasizes a strategy centered on biologically driven precision medicine and disciplined clinical execution.

Key executives include:

• Brian F. Sullivan – Chief Executive Officer
• Wendy Short – Chief Financial Officer

The company was founded by Robert J. Berns, whose academic and scientific background informed the development of the CELsignia® platform. Celcuity’s governance structure aligns with standard U.S. public biotechnology company practices, with oversight provided by a board comprising industry, scientific, and financial expertise.